Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Arbourmarkon Apr 02, 2021 11:38am
157 Views
Post# 32932001

RE:RE:RE:RE:RE:RE:RE:This game isn’t over $$$

RE:RE:RE:RE:RE:RE:RE:This game isn’t over $$$Arch Bio Partners is the real deal. They definitely have credibility as Federal government gave them close to $7M grant toward their phase 2 Covid study. They have phase 2 trials going in Turkey, two hospitals in Calgary and one in  Fort Lauderdale.

The phase 2 study must have shown positive results as the Turkish Health Authority extended the Phase 2 to dose another 20 patients.

The company has no debt, no outstanding warrants very small float and high insider ownership and no need for further dilution.

I suspect once phase 2 of study is completed and data analyzed and if positive results are seen it may get emergency use authorization and proceed into Phase 3 study with large US University Hospital. The fact Canadian Federal Government provided large $7M grant towards phase 2, I would not be surprised that they provide additional funding for Phase 3.
<< Previous
Bullboard Posts
Next >>